168 related articles for article (PubMed ID: 38588626)
41. SERDs: a case study in targeted protein degradation.
Wang L; Sharma A
Chem Soc Rev; 2022 Oct; 51(19):8149-8159. PubMed ID: 36073297
[TBL] [Abstract][Full Text] [Related]
42. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
43. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
Szostakowska M; Trębińska-Stryjewska A; Grzybowska EA; Fabisiewicz A
Breast Cancer Res Treat; 2019 Feb; 173(3):489-497. PubMed ID: 30382472
[TBL] [Abstract][Full Text] [Related]
44. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
45. Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.
Deng X; Deng X; Ning W; Xin L; Li Q; Hu Z; Xie B; Liang K; Min C; Dong C; Huang J; Zhou HB
J Med Chem; 2023 Aug; 66(16):11094-11117. PubMed ID: 37584263
[TBL] [Abstract][Full Text] [Related]
46. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
[TBL] [Abstract][Full Text] [Related]
48. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
Haines CN; Wardell SE; McDonnell DP
Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
[TBL] [Abstract][Full Text] [Related]
49. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K
Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531
[TBL] [Abstract][Full Text] [Related]
50. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
51. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
52. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.
Molina L; Figueroa CD; Bhoola KD; Ehrenfeld P
Expert Opin Ther Targets; 2017 Aug; 21(8):755-766. PubMed ID: 28671018
[TBL] [Abstract][Full Text] [Related]
53. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
54. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
55. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
56. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T; El Ezzy M; Gleason JL; Mader S
J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
[TBL] [Abstract][Full Text] [Related]
57. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
[TBL] [Abstract][Full Text] [Related]
58. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
59. Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer.
Fanning SW; Greene GL
Endocrinology; 2019 Apr; 160(4):759-769. PubMed ID: 30753408
[TBL] [Abstract][Full Text] [Related]
60. Estrogen receptors as therapeutic targets in breast cancer.
Ariazi EA; Ariazi JL; Cordera F; Jordan VC
Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
